Warren Michelle P, Miller K K, Olson W H, Grinspoon S K, Friedman A J
Columbia University, College of Physicians and Surgeons, Department of Obstetrics and Gynecology, PH 16-128, New York, NY 10032, USA.
Contraception. 2005 Sep;72(3):206-11. doi: 10.1016/j.contraception.2005.03.007.
The effects of long-term triphasic oral contraceptive administration on bone mineral density (BMD) were investigated in premenopausal women with hypothalamic amenorrhea (HA) and osteopenia.
After completing three 28-day cycles in the double-blind phase of a placebo-controlled trial, women (mean age, 26.7 years) who received norgestimate 180-250 microg/ethinyl estradiol 35 microg (NGM/EE, n = 15) or placebo (n = 12) in the double-blind phase were to receive open-label NGM/EE for 10 additional cycles.
For subjects completing > or =10 NGM/EE treatment cycles, mean posteroanterior total lumbar spine BMD (L1-L4) increased from 0.881+/-0.0624 g/cm2 at baseline (last visit prior to NGM/EE) to 0.894+/-0.0654 g/cm2 at final visit (p = .043); no significant changes in hip BMD occurred. Decreases in N-telopeptide, osteocalcin, procollagen type I propeptide and bone-specific alkaline phosphatase levels indicated effects on bone metabolism.
Long-term administration of triphasic NGM/EE to osteopenic women with HA may increase total lumbar spine BMD.
研究长期服用三相口服避孕药对下丘脑性闭经(HA)和骨质减少的绝经前女性骨矿物质密度(BMD)的影响。
在一项安慰剂对照试验的双盲阶段完成三个28天周期后,双盲阶段接受诺孕酯180 - 250微克/炔雌醇35微克(NGM/EE,n = 15)或安慰剂(n = 12)的女性(平均年龄26.7岁)将接受开放标签的NGM/EE额外10个周期的治疗。
对于完成≥10个NGM/EE治疗周期的受试者,腰椎前后位总骨密度(L1 - L4)从基线时(NGM/EE治疗前的最后一次访视)的0.881±0.0624克/平方厘米增加到末次访视时的0.894±0.0654克/平方厘米(p = 0.043);髋部骨密度无显著变化。N - 端肽、骨钙素、I型前胶原肽和骨特异性碱性磷酸酶水平降低表明对骨代谢有影响。
长期给患有HA的骨质减少女性服用三相NGM/EE可能会增加腰椎总骨密度。